Nilogen Oncosystems announces the appointment of Eolas Biosciences as its exclusive business partner in Japan for marketing the 3D-EXplore tumoroid platform
Nilogen Oncosystems announces the appointment of Eolas Biosciences as its exclusive business partner in Japan for marketing the 3D-EXplore tumoroid platform
July 1, 2021
Partnership with Eolas augments Nilogen’s continued growth, providing advanced translational oncology services for biotech and pharmaceutical clients in Japan.
Tampa, Florida, July 1, 2021 – Nilogen Oncosystems is a global oncology drug development leader providing advanced translational oncology services with its unique 3D-EXplore platform. Through its partnership with Eolas, Nilogen will expand its relationships with both its existing and new clients in Japan.
“Nilogen’s partnership with Eolas will enable us to continue our global expansion, providing our clients with local expertise and support in Japan” said Jon Waterman-Smith, VP of Business Development and Marketing at Nilogen. “This relationship brings together the complementary strengths of both companies to enhance our ability to support our clients in Japan”.
“We are delighted to partner with Nilogen, to help enhance their business development and client support in Japan” said Ruairí Mac Síomoín, Managing Director at Eolas. “Nilogen’s exciting new 3D-EXplore platform is transforming the way oncology drug development companies are translating all forms of oncology therapeutics and combinations into the clinic from small molecules to monoclonals, multi-specifics, ADCs, ADCCs, ACTs and oncolytic viruses”.
About Nilogen Oncosystems
Nilogen Oncosystems is a leading oncology drug development company providing advanced translational oncology services with its unique 3D-EXplore platform. Nilogen’s mission is to improve the treatment and quality of life for cancer patients by helping companies develop oncology therapies of the future by improving their chance of success in clinical trials. It achieves this through the application of game-changing human tumor tissue assays which provide a comprehensive analysis of drug impact on the immune compartment as well as tumor cells. For more information, visit www.nilogen.com.
Company Inquiries
Jon Waterman-Smith
Nilogen Oncosystems, LLC
+1 813 440 3588
About Eolas Biosciences
Eolas Biosciences is a Japan-based specialist business development firm focused on supporting drug discovery research by helping overseas companies with cutting-edge or best-in-class technologies to succeed in the Japanese pharmaceutical research market. Conversant with a wide range of drug discovery technologies, Eolas has over 15 years’ experience of successfully supporting innovative overseas companies in Japan. For more information, visit: www.eolas-bio.co.jp (Japanese) or www.eolas-bio.com (English).
3D-Explore information: https://eolas-bio.co.jp/3d-explore (Japanese)
Company Inquiries
Ruairí Mac Síomoín
Eolas Biosciences Co. Ltd.
+81-47-308-2204
